KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $36.9 million.

  • Travere Therapeutics' Share-based Compensation rose 40.40% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 18.90%. This contributed to the annual value of $36.9 million for FY2024, which is 16.57% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Share-based Compensation is $36.9 million, which was down 16.57% from $44.2 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Share-based Compensation registered a high of $44.2 million during FY2023, and its lowest value of $23.6 million during FY2020.
  • Over the past 3 years, Travere Therapeutics' median Share-based Compensation value was $38.1 million (recorded in 2022), while the average stood at $39.8 million.
  • As far as peak fluctuations go, Travere Therapeutics' Share-based Compensation climbed by 29.01% in 2022, and later fell by 16.57% in 2024.
  • Over the past 5 years, Travere Therapeutics' Share-based Compensation (Yearly) stood at $23.6 million in 2020, then increased by 25.21% to $29.6 million in 2021, then rose by 29.01% to $38.1 million in 2022, then increased by 16.00% to $44.2 million in 2023, then dropped by 16.57% to $36.9 million in 2024.